Revenue Breakdown
Composition ()
No data
Revenue Streams
Maravai LifeSciences Holdings Inc (MRVI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Nucleic Acid Production, accounting for 60.9% of total sales, equivalent to $25.35M. Another important revenue stream is Biologics Safety Testing. Understanding this composition is critical for investors evaluating how MRVI navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Maravai LifeSciences Holdings Inc maintains a gross margin of 25.75%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -37.02%, while the net margin is -126.37%. These profitability ratios, combined with a Return on Equity (ROE) of -48.64%, provide a clear picture of how effectively MRVI converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MRVI competes directly with industry leaders such as BIOA and SGP. With a market capitalization of $928.01M, it holds a leading position in the sector. When comparing efficiency, MRVI's gross margin of 25.75% stands against BIOA's 100.00% and SGP's N/A. Such benchmarking helps identify whether Maravai LifeSciences Holdings Inc is trading at a premium or discount relative to its financial performance.
